Symbiotec Pharmalab Ltd

AI
Symbiotec Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Symbiotec Pharmalab Ltd

₹ 1,100 -1.89%
23 Sep 10:51 a.m.
symbiotec.com BSE: 544889 NSE: SYMBIOTEC
About

Symbiotec is a research-driven, science-
based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal
Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale
Steroid manufacturer into a fully integrated global platform.[1]

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 7,069 Cr.
  • Current Price ₹ 1,100
  • High / Low ₹ 1,194 / 934
  • Stock P/E 44.6
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 21.4 %
  • ROE 17.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company's working capital requirements have reduced from 68.5 days to 47.6 days

Cons

  • The company has delivered a poor sales growth of 6.29% over past five years.
  • Promoter holding is low: 33.3%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE IPO Nifty IPO

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2025 Mar 2026 Jun 2026
204 213 211
142 164 152
Operating Profit 62 49 59
OPM % 31% 23% 28%
11 -34 20
Interest 5 6 6
Depreciation 9 11 10
Profit before tax 59 -3 63
Tax % 25% 430% 25%
45 -16 47
EPS in Rs 69.90 -2.50 7.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
623 634 564 674 757 845
420 529 483 531 538 605
Operating Profit 202 105 80 143 219 241
OPM % 32% 17% 14% 21% 29% 28%
9 6 -52 20 32 -4
Interest 7 3 8 8 17 24
Depreciation 22 25 28 37 38 39
Profit before tax 183 83 -8 118 196 173
Tax % 26% 25% 191% 25% 26% 33%
136 62 -23 89 146 116
EPS in Rs 123.95 56.44 -20.72 81.33 229.01 18.46
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 6%
3 Years: 14%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: 3%
3 Years: 40%
TTM: 7%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 16%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 11 11 11 11 11
Reserves 622 684 662 750 900
47 64 107 52 293
161 136 135 274 145
Total Liabilities 842 894 915 1,087 1,348
248 266 266 324 317
CWIP 27 23 74 19 59
Investments 123 130 66 42 44
445 476 510 702 928
Total Assets 842 894 915 1,087 1,348

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
158 24 93 147 83
-79 -34 -132 -81 -292
-79 15 37 -63 225
Net Cash Flow -0 4 -3 4 16
Free Cash Flow 116 -18 22 107 8
CFO/OP 99% 45% 136% 128% 54%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 70 83 73 68 85
Inventory Days 309 250 304 378 309
Days Payable 151 86 109 254 101
Cash Conversion Cycle 228 246 268 191 293
Working Capital Days 111 137 110 105 53
ROCE % 12% 8% 16% 21%

Shareholding Pattern

Numbers in percentages

23 Recently
Sep 2026
33.28%
21.08%
27.51%
18.12%
No. of Shareholders 4,27,730

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls

  • Sep 2026
    Transcript
    PPT REC